Lupin Ltd (LUPIN)

📊 Quarterly Results (₹ Cr)

Lupin's quarterly revenue has risen sequentially for four consecutive periods, from ₹7,048 crore in September 2025 to ₹8,277 crore in June 2026, indicating consistent top-line growth. While operating profit margin dipped slightly from 28.7% to 24.1% over the same period, this appears aligned with management's commentary on pricing dynamics in competitive markets. Net profit remains stable around ₹1,400 crore quarter-on-quarter, with EPS tracking closely, suggesting disciplined cost management despite margin headwinds.

🔮 Management Outlook & What's Next

Management has not provided formal forward guidance on revenue or margins in the latest filings, but the ESG rating announcement and AGM resolutions suggest a focus on long-term sustainability and operational continuity. The reappointment of Deloitte as auditor and approval of cost auditor remuneration indicate confidence in audit processes and financial controls. No explicit targets were disclosed for FY27 performance, but the consistent dividend declaration and ESG recognition reflect a strategy centered on stability, governance, and stakeholder trust.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

The balance sheet shows a steady increase in total assets from ₹29,205 crore (March 2025) to ₹38,365 crore (March 2026), driven by growth in reserves and investments. Borrowings remain low and stable at around ₹5,900–6,200 crore, with debt-to-equity held at a conservative 0.26, indicating minimal leverage. Equity has remained flat at ₹91 crore, suggesting retained earnings are being absorbed into reserves rather than capital restructuring. This points to a capital-light growth model with reinvestment focused on organic expansion rather than debt-funded acquisitions.

💰 Cash Flow Statement (₹ Cr)

👥 Shareholding Pattern

Promoter holding has remained stable near 46.85–46.9% over the past year, suggesting confidence in long-term prospects. In contrast, Foreign Institutional Investor (FII) ownership has risen from 20.49% in Q2FY26 to 22.42% in Q1FY27, indicating growing international interest. Domestic Institutional Investor (DII) share has declined slightly from 26.55% to 24.65%, but the increase in public shareholders and overall shareholder base (from 2,80,256 to 3,00,283) reflects rising retail and passive fund participation, enhancing liquidity and market breadth.

⚖️ Peer Comparison — Pharmaceuticals

🔗 Peer Stock Analyses

⚠️ Risk Factors

1. Margin pressure persists despite revenue growth, with OPM declining from 28.7% to 24.1% over four quarters, potentially due to pricing competition in domestic formulation markets. 2. High concentration in emerging markets exposes Lupin to currency volatility and regulatory scrutiny, particularly in the US and Latin America. 3. Regulatory risks remain elevated given the company's reliance on complex generics and global approval cycles, with no recent pipeline updates disclosed. 4. ESG ratings, while positive, are non-financial and may not translate directly into operational or revenue benefits without complementary disclosures.

📋 Recent Filings

• Announcement2026-09-28Lupin Ltd announced that its insider trading window will close on October 1, 2026, and remain shut until 48 hours after the unaudited Q2 results for S…
• 🔴 Announcement2026-09-28Lupin announced that its U.S. subsidiary received tentative FDA approval for a novel apixaban oral suspension formulation, expanding administration op…
• 🔴 Corporate Action2026-09-21Lupin announced on September 21, 2026, the allotment of 24,111 fully paid-up equity shares of ₹2 each under its ESOP, increasing the issued and paid-u…
• 🔴 Announcement2026-09-08Lupin Ltd announced its participation in two upcoming investor events: the Kotak Healthcare Conference on September 17, 2026, and the J.P. Morgan Indi…
• 🔴 Announcement2026-09-04Lupin announced that the U.S. FDA approved its ANDA for Modafinil Tablets USP 100 mg and 200 mg, marking the company's first product launch in the U.S…
• 🔴 Announcement2026-08-28Lupin Limited announced it received an ESG rating of Crisil ESG 69 and a Core ESG rating of Crisil Core ESG 65 for FY26 from Crisil ESG Ratings, an in…
• Announcement2026-08-24Lupin Limited disclosed an independent ESG rating of 60 from ESG Risk Assessments & Insights Limited, placing it in the 'Adequate' category under SEBI…
• Announcement2026-08-20Lupin announced that its Dutch subsidiary VISUfarma entered an exclusive license agreement with Visus Therapeutics to commercialize YUVEZZI, a dual-ag…
• Announcement2026-08-18Lupin Limited announced the death of Dr. Sofia Mumtaz, President of Legal & Compliance for Canada, ANZ and NEA, effective August 17, 2026. Her passing…
• Announcement2026-08-17Lupin Limited announced that the U.S. FDA approved its Abbreviated New Drug Application for Pitolisant Tablets, 4.45 mg and 17.8 mg, as bioequivalent …

🧠 Analyst's Read

Lupin is executing a stable, capital-efficient strategy with consistent financial performance and growing ESG credibility, supported by strong returns and disciplined capital allocation. The key watchpoint is whether margin recovery can materialize amid pricing pressures, especially as the company expands in regulated international markets. Investors should monitor upcoming product launches and regulatory outcomes for signs of sustainable growth.

Based on filing content and financial data. Not a recommendation.